The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Evolving treatment concepts in liver cancer in 2026
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China explores the evolving treatment landscape for liver cancer. There is evidence that local or regional therapy could change the immune environment of the liver, allowing synergy with immunotherapy. Traditionally, local therapy would be expected to remove the tumor completely, however now evidence suggests that systemic and local therapy could be combined to produce a synergistic effect and improve the durability of response. In addition, the addition of local therapy to immunotherapy could prevent the development of resistant clones to improve patient outcomes. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
